Retatrutide Phase 3: The 28.7% Number, In Context

For context: this is roughly 6 percentage points higher than tirzepatide's Phase 3 SURMOUNT-1 at the comparable dose. It's approaching bariatric-surgery territory (typical gastric bypass: 30–35% weight loss at 1–2 years, though long-term rebound narrows that gap).

Why retatrutide is different

Retatrutide is a triple agonist. It activates three receptors simultaneously:

1. GLP-1 — the receptor semaglutide hits. Slows gastric emptying, reduces appetite, modulates insulin.
2. GIP — the second receptor tirzepatide adds. Amplifies GLP-1's insulin effect, supports lean mass retention.
3. Glucagon — the receptor semaglutide and tirzepatide leave alone. Drives energy expenditure, mobilizes hepatic glucose, increases lipolysis.

The glucagon arm is what separates retatrutide from its dual-agonist cousin. Glucagon traditionally raises blood glucose — which is why it's counterintuitive in a diabetes drug. But in the presence of strong GLP-1 and GIP activation, the glucose-raising effect is suppressed while the thermogenic and fat-mobilizing effects remain.

It's the first major obesity drug that increases metabolic rate rather than just suppressing intake.

What TRIUMPH-4 actually reported

Breaking down the top-line:

What the headline number hides

The 28.7% is a mean. Individual responses will be distributed around it. The full trial publication (expected 2026) will reveal:

• The responder / non-responder breakdown
• Lean-mass versus fat-mass composition (critical — is the weight loss muscle?)
• Metabolic health markers beyond weight (A1C, liver enzymes, blood pressure)
• Adverse events, particularly GI and pancreatic

As with every GLP-1 class drug so far, real-world effectiveness tends to underperform trial results by a meaningful margin. GHUSN et al. (2024) showed real-world semaglutide users averaged ~5% weight loss at one year versus the ~15% in STEP trials — mainly because of discontinuation rates.

The TRIUMPH-OA finding

TRIUMPH-OA was a substudy specifically evaluating retatrutide in participants with knee osteoarthritis. Key finding: substantial pain reduction alongside weight loss, beyond what weight loss alone would predict.

This matters. If retatrutide produces independent anti-inflammatory or joint-beneficial effects via its glucagon receptor arm, we're looking at a drug that treats two conditions — obesity and OA — simultaneously. It also strengthens the case for retatrutide's cardiovascular benefit, which is being studied in TRIUMPH-4.

What's next

How to think about retatrutide today

• If you're a physician or researcher: This is landscape-changing data. The triple-agonist class appears to meaningfully outperform dual agonists. Plan education around this transition.
• If you're considering it for personal use: Retatrutide is not yet FDA-approved. Compounded versions are circulating and sold by research-chemical suppliers. Quality and safety are uncharacterized at that source. Wait for approval or use one of the approved GLP-1s under proper medical supervision.
• If you're a semaglutide/tirzepatide patient: No urgency to switch. Both are FDA-approved with known real-world outcomes. Retatrutide will be available eventually.

Cardiovascular surprise

A smaller but underreported finding from TRIUMPH-4 is the cardiovascular risk marker reduction. Systolic BP dropped an average 8 mmHg. LDL decreased ~12%. Triglycerides fell ~20%. These numbers are consistent with what we'd expect from ~30% weight loss — but they compound into a potentially substantial MACE reduction if SELECT-style analysis holds.

The dedicated cardiovascular outcomes trial for retatrutide is underway and expected to read out in 2027.

The FDA question

For retatrutide to get approved, Lilly needs:

1. Safety data holding up across the full TRIUMPH program (watch for pancreatitis, thyroid, GI discontinuation rates)
2. Manufacturing scale-up — these triple-agonists are more complex peptides
3. FDA willingness to approve a fourth major GLP-1-class drug in a crowded market

All three look plausible. The main risk is a late-emerging safety signal. Semaglutide and tirzepatide faced similar scrutiny and cleared it.